Plasma interleukin-10: A likely predictive marker for hepatitis B virus-related acute-on-chronic liver failure

Hepatitis Monthly

Volumn 14, Issue 7, 2014, Pages

  Wang, Ke ^a   Wu, Zhe Bin ^a   Ye, Yi Nong ^b   Liu, Jing ^a   Zhang, Geng Lin ^a   Su, Yu Jie ^a   He, Hong Liang ^a   Zheng, Yu Bao ^a   Gao, Zhi Liang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Foshan First Municipal People's Hospital   (China)

Author keywords

Chronic hepatitis B; Chronic liver failure; Cytokines; Interleukin 10; Severe exacerbation

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; IMMUNOMODULATION; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROTHROMBIN TIME;

EID: 84905659894     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.19370     Document Type: Article

References (25)

1. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol int. 2012;6(3):531-61.
2. You S, Rong Y, Zhu B, Zhang A, Zang H, Liu H, et al. Changing etiology of liver failure in 3,916 patients from northern China: a 10-year survey. Hepatol Int. 2013;7(2):714-20.
3. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int. 2013;33(1):40-52.
4. Zheng YB, Huang ZL, Wu ZB, Zhang M, Gu YR, Su YJ, et al. Dynamic changes of clinical features that predict the prognosis of acuteon-chronic hepatitis B liver failure: a retrospective cohort study. Int J Med Sci. 2013;10(12):1658-64.
5. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012;57(6):1336-48.
6. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820-8.
7. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55(8):2373-80.
8. Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A metaanalysis and meta-regression. Exp Ther Med. 2013;6(4):929-36.
9. Zhang GL, Xie DY, Lin BL, Xie C, Ye YN, Peng L, et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acuteon-chronic liver failure. J Gastroenterol Hepatol. 2013;28(3):513-21.
10. Fujiwara K, Yasui S, Yonemitsu Y, Mikata R, Arai M, Kanda T, et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2014;44(5):491-501.
11. Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43(9):711-9.
12. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3(1):269-82.
13. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89(4):732-5.
14. Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, et al. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat. 2009;16(7):464-70.
15. Matsumoto K, Miyake Y, Miyatake H, Takahara M, Imada T, Yagi S, et al. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J Gastroenterol. 2009;15(13):1650-2.
16. Zou Z, Li B, Xu D, Zhang Z, Zhao JM, Zhou G, et al. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-onchronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol. 2009;43(2):182-90.
17. Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat. 2011;18(7):458-67.
18. Shen C, Yan WZ, Zhao CY, Che HH, Liu XY, Liu ZZ, et al. Increased CD4CD25 regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. J Microbiol Immunol Infect.2013.
19. Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012;189(8):3925-35.
20. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):1-8.
21. Sofian M, Kalantar E, Aghakhani A, Hosseini S, Banifazl M, Eslamifar A, et al. No correlation between interleukin-10 gene promoter polymorphisms and hepatitis B virus infection outcome. Hepat Mon. 2013;13(5).
22. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000;118(4):655-60.
23. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003;38(4):859-68.
24. Sagnelli E, Manzillo G, Maio G, Pasquale G, Felaco FM, Filippini P, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet. 1980;2(8191):395-7.
25. Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612-21.